Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
Washingtoner/10336050

ORLANDO, Fla. - Washingtoner -- Nutriband Inc. (N A S D A Q: NTRB) delivered one of its most notable trading sessions of 2026 on September 24, breaking through its previous 52-week high and reaching $9.00 intraday before closing at $8.99, a gain of approximately 22.31% on the day. Trading volume reached roughly 382,000 shares, substantially above the approximately 130,000 shares traded on September 23. Current market data places NTRB's 52-week range at approximately $2.80–$9.00.

The move represents another dramatic step in a September rally that has brought NTRB from a $4.72 September 3 opening price to today's $8.99 close. The stock has therefore gained roughly 90% from that September 3 opening level, while the September 24 session alone added $1.64 per share.

For investors watching the company, however, the stock-price breakout is occurring at an especially interesting time.

Nutriband is simultaneously approaching a major warrant deadline, advancing intellectual-property and commercialization initiatives surrounding AVERSA™, and increasing its visibility within the Nasdaq life-sciences community.

A New 52-Week High Changes the Conversation

Today's trading session was significant not simply because NTRB rose sharply, but because the stock pushed into a new 52-week high of $9.00.

NTRB opened at $7.35, traded as low as $7.35, and then climbed to $9.00 before finishing at $8.99.

That represents a remarkable intraday move of approximately 22.4% from the opening price and puts the stock firmly into new territory for the trailing 52-week period.

The progression throughout September is also notable:

• Sept. 3: closed at $5.63
• Sept. 11: closed at $6.96
• Sept. 17: closed at $7.65
• Sept. 18: closed at $8.13
• Sept. 23: closed at $7.35
• Sept. 24: $9.00 intraday / $8.99 close

The stock's September momentum is therefore occurring against a backdrop of substantial volatility rather than a straight-line advance. That distinction is important for investors evaluating what happens next.

More on Washingtoner

• Spokane: City Creates Reduced Utility Rates for Micro-Sized Living Units
• Spokane: Daughters of the American Revolution Dedicate "Never Forget Garden" in Riverfront Park to Honor Veterans
• Spokane: Police Arrest Registered Sex Offender for Child Sexual Abuse Material
• JaapDaily passes 22 million chants, adds big-screen Recite Along view for Navratri
• valueGLASS Calls for Independent Choice as Safelite Absorbs Kitsap Competitor

The Warrant Clock Is Now Ticking Loudly

One of the biggest near-term developments surrounding NTRB is the company's publicly traded warrants, N A S D A Q: NTRBW.

And there has been an important update since our previous article.

On September 22, Nutriband officially confirmed that the outstanding publicly traded warrants will expire September 30, 2026 at 5:00 p.m. Eastern Time. The company specifically stated that it will not extend or reprice the warrants.

There are currently 910,904 warrants outstanding, each with a $6.43 exercise price. If every one of those warrants were exercised at $6.43, Nutriband would receive approximately $5.856 million in gross proceeds.

With NTRB closing today at $8.99, the common stock is approximately $2.56 above the $6.43 warrant exercise price.

That creates a particularly interesting situation heading into the final trading days before expiration.

Warrants that are not exercised by the deadline will expire and become void. The company has also confirmed that trading in NTRBW will cease at the close of trading on September 30.

For investors, the key numbers are now unmistakable:

910,904 — public warrants outstanding
$6.43 — exercise price
$5.856 million — potential gross proceeds if fully exercised
September 30, 2026 — expiration at 5:00 p.m. ET

AVERSA™ Remains the Bigger Story

While today's stock move is attracting attention, the fundamental development story remains Nutriband's AVERSA™ abuse-deterrent transdermal technology.

Nutriband is developing AVERSA™ Fentanyl as an abuse-deterrent fentanyl transdermal system designed to address risks associated with abuse, misuse, diversion and accidental exposure.

The company has described AVERSA™ as a platform that can be incorporated into transdermal patches containing drugs with abuse potential. Nutriband's broader AVERSA development pipeline includes additional potential applications beyond fentanyl.

Importantly, the company has also reported AVERSA-related patent protection in 46 countries, adding an extensive intellectual-property component to the potential commercial opportunity.

USPTO Development Adds Another Piece

Earlier this month, Nutriband announced that it received a USPTO Notice of Publication for commercial brand-name trademarks associated with its lead abuse-deterrent fentanyl transdermal system.

The trademarks are subject to a 30-day opposition period, after which the company could potentially proceed toward a Notice of Allowance. Nutriband has said the proposed commercial brand name and product labeling are intended for submission to the FDA and international regulatory agencies as part of its development strategy.

More on Washingtoner

• Jacqui Condon Selected to Workers' Compensation Panels for Three Professional Athlete Associations
• Tacoma: Community Event Funding Announced for 2027
• New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
• Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
• PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team

The company has previously estimated potential peak annual U.S. sales for its abuse-deterrent fentanyl product in the range of $80 million to $200 million. That figure is a company projection, not current revenue or a guarantee of future sales.

Nasdaq Visibility Continues to Grow

Nutriband CEO Gareth Sheridan also participated in the inaugural N A S D A Q Life Sciences Advisory Board (LaB) Biotech Summit at Nasdaq MarketSite in New York on September 16.

The event brought together biotechnology executives, investors and industry participants and provided another opportunity for Nutriband management to present the company's story within the broader life-sciences investment community.

A Particularly Interesting Moment for NTRB

Today's new 52-week high arrives with several important developments converging simultaneously.

The stock has broken into new 52-week territory.

The September 30 warrant expiration is only days away.

The $6.43 warrant exercise price remains well below today's $8.99 closing price.

Up to approximately $5.856 million in gross proceeds could result if all 910,904 public warrants are exercised.

AVERSA™ continues progressing toward its potential commercialization pathway.
The company's intellectual-property and trademark position continues developing.

For prospective investors, that combination makes the next several trading sessions particularly important to watch.

Today's $9.00 52-week high and $8.99 close mark a clear technical milestone for Nutriband. At the same time, the company is approaching the end of a significant warrant window that could potentially provide additional capital while it continues developing AVERSA™.

The next chapter will ultimately depend on execution — including regulatory progress, financing, commercialization, intellectual-property development and the company's ability to advance its pipeline.

But with NTRB now trading at a new 52-week high, AVERSA™ continuing forward, and the NTRBW warrant deadline arriving September 30, Nutriband has certainly entered a period that warrants close attention as September comes to an end.

For more information on NTRB visit: https://www.nutriband.com

Nutriband, Inc.
121 South Orange Avenue
Suite 1500
Orlando, Fl 32801
Phone: 407-377-6695
Email: info@nutriband.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website